Progyny (PGNY) Common Equity (2018 - 2026)

Progyny (PGNY) has reported Common Equity for 9 consecutive years, with $453.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 11.99% year-over-year to $453.3 million in Q2 2026; TTM through Jun 2026 was $453.3 million, a 11.99% decrease from a year earlier, with the FY2025 full-year figure at $516.0 million, up 22.27% from the prior year.
• Common Equity was $453.3 million for Q2 2026 at Progyny, up from $439.3 million in the prior quarter.
• Over five years, Common Equity peaked at $571.6 million in Q1 2024 and troughed at $279.6 million in Q1 2022.
• A 5-year average of $450.7 million and a median of $454.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 54.77% in 2022 and decreased 23.74% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $377.0 million in 2022, then soared by 46.81% to $553.4 million in 2023, then declined by 23.74% to $422.1 million in 2024, then advanced by 22.27% to $516.0 million in 2025, then declined by 12.17% to $453.3 million in 2026.
• The last three Common Equity figures came in at $453.3 million (Q2 2026), $439.3 million (Q1 2026), and $516.0 million (Q4 2025), per Business Quant data.